Drug Pipeline

Enzalutamide Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
64
Active Studies
41
Recruiting
19
Phase 3
10
Top Sponsors
15
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-10 NCT06592924
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration…
Trial sites expanded: 340 -> 368 locations
2026-06-05 NCT07287150
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant…
Trial sites expanded: 20 -> 32 locations
2026-06-04 NCT03344211
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic…
date change Primary completion pushed: 2026-11-21 -> 2026-12-31
2026-06-04 NCT03344211
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic…
date change Completion pushed: 2027-11-21 -> 2027-12-31
2026-06-04 NCT06136650
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA)…
Trial sites expanded: 324 -> 327 locations
2026-06-03 NCT07226986
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan…
Trial sites expanded: 12 -> 17 locations
2026-05-29 NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat…
Trial sites expanded: 305 -> 329 locations
2026-05-28 NCT06120491
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate…
overall status: "Recruiting" → "Active Not Recruiting"
2026-05-28 NCT06120491
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate…
Trial sites reduced: 410 -> 322 locations
2026-05-28 NCT06120491
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate…
date change Primary completion moved earlier: 2028-01-11 -> 2027-09-30
2026-05-23 NCT07028853
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat…
Trial sites expanded: 302 -> 305 locations
2026-05-23 NCT03860987
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using…
Trial completed
2026-05-23 NCT03860987
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using…
date change Primary completion moved earlier: 2026-07-31 -> 2026-05-11
2026-05-23 NCT03860987
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using…
date change Completion moved earlier: 2028-08-01 -> 2026-05-18
2026-05-16 NCT06691984
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy…
overall status: "Recruiting" → "Active Not Recruiting"
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-02 NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… Phase 3 Not Yet Recruiting
2026-05-28 NCT07611110 AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant… Phase 3 Recruiting
2026-05-18 NCT07592910 A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have… Phase 2 Not Yet Recruiting
Active Studies by Phase
Phase 4
2
Phase 3
19
Phase 2
23
Phase 1/2
10
Phase 1
8
Not specified
2
Active Trials — top 25 of 64
NCT IDTitleConditionStatus
Phase 4
NCT03016741 Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer Castration-Resistant Prostatic Cancer Active, Not Recruiting
NCT05457257 Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With… Metastatic Castration-resistant Prostate Cancer Active, Not Recruiting
Phase 3
NCT06136624 Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) Prostate Cancer Metastatic Recruiting
NCT06764485 A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice… Metastatic Castration-resistant Prostate Cancer Recruiting
NCT06520345 The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT… Metastatic Castration-resistant Prostate Cancer Recruiting
NCT07611110 AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant… Metastatic Castration-resistant Prostate Cancer Recruiting
NCT06629779 A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic… Metastatic Castration-Resistant Prostate Cancer Recruiting
NCT06136650 A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA)… Metastatic Castration-resistant Prostate Cancer (mCRPC) Recruiting
NCT06592924 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration… Prostate Cancer (Adenocarcinoma) Recruiting
NCT07028853 This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat… Metastatic Castration Sensitive Prostate Cancer (mCSPC) Recruiting
NCT04647526 Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line… Metastatic Castration-Resistant Prostate Cancer Active, Not Recruiting
NCT04455750 A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With… Castration-Resistant Prostate Carcinoma Active, Not Recruiting
NCT05112965 An Extension Study in Participants Previously Enrolled in a Genentech and/or F… Neoplasms Active, Not Recruiting
NCT04076059 An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT)… Metastatic Hormone Sensitive Prostate Cancer Active, Not Recruiting
NCT03768063 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd… Cancer Active, Not Recruiting
NCT06551324 A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in… Metastatic Castrate Resistant Prostate Cancer (mCRPC) Active, Not Recruiting
NCT02446444 Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk… Prostatic Neoplasms Active, Not Recruiting
NCT02319837 Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic… Hormone Sensitive Prostate Cancer Active, Not Recruiting
NCT06691984 Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy… Metastatic Castration-resistant Prostate Cancer Active, Not Recruiting
NCT06120491 Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate… Metastatic Castration-Sensitive Prostate Cancer Active, Not Recruiting
NCT07620574 Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored… Cancer Not Yet Recruiting
Phase 2
NCT06059118 Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic… Prostate Cancer Recruiting
NCT06099769 A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy… Metastatic Breast Cancer Recruiting
NCT05726292 A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus… Prostate Cancer Recruiting
NCT05751941 Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic… Prostate Cancer Recruiting
Sponsors Running Enzalutamide Trials
Disease Areas
Get alerts when Enzalutamide trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free